Mycophenolic Acid overcomes imatinib and nilotinib resistance of chronic myeloid leukemia cells by apoptosis or a senescent-like cell cycle arrest. by Drullion, Claire et al.
Mycophenolic Acid overcomes imatinib and nilotinib
resistance of chronic myeloid leukemia cells by apoptosis
or a senescent-like cell cycle arrest.
Claire Drullion, Vale´rie Lagarde, Romain Gioia, Patrick Legembre, Muriel
Priault, Bruno Cardinaud, Eric Lippert, Franc¸ois-Xavier Mahon, Jean-Max
Pasquet
To cite this version:
Claire Drullion, Vale´rie Lagarde, Romain Gioia, Patrick Legembre, Muriel Priault, et al.. My-
cophenolic Acid overcomes imatinib and nilotinib resistance of chronic myeloid leukemia cells
by apoptosis or a senescent-like cell cycle arrest.. Leukemia Research and Treatment, 2012,
2012, pp.861301. <10.1155/2012/861301>. <hal-00846103>
HAL Id: hal-00846103
https://hal.archives-ouvertes.fr/hal-00846103
Submitted on 16 Oct 2013
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
Hindawi Publishing Corporation
Leukemia Research and Treatment
Volume 2012, Article ID 861301, 9 pages
doi:10.1155/2012/861301
Research Article
Mycophenolic Acid Overcomes Imatinib and
Nilotinib Resistance of Chronic Myeloid Leukemia Cells by
Apoptosis or a Senescent-Like Cell Cycle Arrest
Claire Drullion,1 Vale´rie Lagarde,1 Romain Gioia,1 Patrick Legembre,2 Muriel Priault,3
Bruno Cardinaud,1 Eric Lippert,1 Franc¸ois-Xavier Mahon,1 and Jean-Max Pasquet1
1Laboratoire He´matopoı¨e`se Leuce´mique et Cibles The´rapeutiques, INSERM U1035, Universite´ Bordeaux Se´galen,
146 Rue Le´o Saignat Bat TP 4e e´tage, 33076 Bordeaux, France
2 IRSET, EA 4427 SERAIC, Universite´ Rennes-1, 2 Avenue du Professeur Le´on Bernard, 35043 Rennes, France
3 IBGC, UMR CNRS 5095, Universite´ Bordeaux Se´galen, 1 Rue Camille Saint Sae¨ns, 33077 Bordeaux, France
Correspondence should be addressed to Jean-Max Pasquet, jean-max.pasquet@u-bordeaux2.fr
Received 30 September 2011; Accepted 16 November 2011
Academic Editor: Judith E. Karp
Copyright © 2012 Claire Drullion et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
We used K562 cells sensitive or generated resistant to imatinib or nilotinib to investigate their response to mycophenolic acid
(MPA). MPA induced DNA damage leading to cell death with a minor contribution of apoptosis, as revealed by annexin V labeling
(up to 25%). In contrast, cell cycle arrest and positive staining for senescence-associated β-galactosidase activity were detected
for a large cell population (80%). MPA-induced cell death was potentialized by the inhibition of autophagy and this is associated
to the upregulation of apoptosis. In contrast, senescence was neither decreased nor abrogated in autophagy deﬁcient K562 cells.
Primary CD34 cells from CML patients sensitive or resistant to imatinib or nilotinib respond to MPA although apoptosis is mainly
detected. These results show that MPA is an interesting tool to overcome resistance in vitro and in vivo mainly in the evolved phase
of the disease.
1. Introduction
Chronic myeloid leukaemia (CML) is a myeloproliferative
disorder characterized by a reciprocal translocation leading
to the Philadelphia chromosome (Ph+) with a fusion gene
BCR-ABL, the molecular hallmark of CML and Ph-positive
acute lymphoblastic leukaemia (LAL) [1–3]. The resulting
chimeric protein contains the kinase domain of the tyrosine
kinase Abl N-terminal fused to a portion of Bcr including its
dimerization domain [1]. The constitutive dimerization of
Bcr-Abl results in the deregulated activation of the tyrosine-
kinase driving uncontrolled proliferation and suppression of
apoptosis in the affected hematopoietic cells. This patho-
physiology explains the remarkable efficacy of Abl tyrosine
kinase inhibitors (TKI) in controlling CML. Indeed, when
exposed to TKI, Bcr-Abl expressing cells undergo apoptosis
[4]. Although TKIs have represented a tremendous progress
in the management of CML patients, resistances to TKI
treatment have emerged. About a third of these resistances
can be explained by the acquisition of additional mutations
in the kinase domain of Abl. These mutations typically
impede the inhibitor binding to its target, and second-
generation inhibitors have been designed to overcome these
resistances whenever possible. In the remaining resistant
patients, the mechanisms are certainly more varied and
often remain elusive. In an attempt to characterize and so
to overcome resistance to TKI, we have generated K562-
derived cell lines resistant to imatinib or nilotinib [5, 6]. We
and other have shown that ampliﬁcation of Bcr-Abl, over-
expression of stress proteins, or deregulation of Src kinases
are among the mechanisms explaining resistance to imatinib
and nilotinib [6–9].
We previously reported that treatment with mycopheno-
lic acid (MPA) could induce CML cell death independently
of the sensitivity to TKI [10]. MPA, an active metabolite
of Mycophenolate mofetil, is a noncompetitive reversible
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inhibitor of IMPDH (Inosine monophosphate dehydroge-
nase; EC1.1.1.205) widely used as an immunosuppressive
drug. MPA reduces the GTP pool resulting in a cycle arrest
mainly in G0/G1 phase although some blockage in S phase is
also reported [11, 12]. It has been reported to act in synergy
with imatinib or methotrexate in Bcr-Abl-positive K562 cells
[13, 14]. MPA is described as a potent necrosis inducer on
activated lymphocytes [15]. Because the level of expression
of IMPDH is increased in leukemic cells in comparison to
normal cells andMPA is able to induce the death of both TKI
sensitive and resistant CML cells, it could be interesting to
identify how CML cells died in response to the agent [16, 17].
The interplay between these mechanisms of cell death in
killing Bcr-Abl expressing cells has not been thoroughly
characterized, especially in the context of resistance to TKI.
In this study, we investigated cell death triggered by MPA in
Bcr-Abl expressing cells. Using K562 and CML primary cells,
we explored how MPA induced cell death and overridden
resistance. In our models, MPA- induced cell deaths mainly
relied on senescence and apoptosis. In addition, TKI-induced
autophagy acts to rescue the cells from apoptosis, but fails to
impair senescence-induced cell death.
2. Materials andMethods
2.1. Reagents. RPMI 1640 medium, fetal calf serum (FCS),
phosphate buffered saline (PBS), trypan blue, mycophenolic
acid, chloroquine, propidium iodide, and the antibody
against LC3 were from Sigma (St Quentin Fallavier, France).
Tyrosine kinase inhibitors Imatinib and Nilotinib were
kindly provided by Novartis Pharma (Basle, Switzerland).
The broad caspase inhibitors Z-VAD-fmk were purchased
from Peptanova (Sandhausen, Germany). The following anti
bodies: caspase 3 was from Cell Signalling (Danvers, USA);
SQSTM1/p62 andHsp60 were from Santa Cruz (Bergheimer,
Germany). Annexin-V-FITC or APC conjugated were from
Beckman coulter (Villepinte, France).
2.2. Cell Lines. The human erythroleukemia Bcr-Abl pos-
itive human cell lines used in this study: K562 was from
ATCC (CCL-243). TKI-resistant cell lines were derived as
previously described for imatinib or nilotinib resistance
and designated K562-R or K562-RN [5, 6, 17]. Cells were
maintained in RPMI 1640 medium (Sigma, R0883) supple-
mented with 10% fetal calf serum (FCS; GIBCO, 10270),
2mM L-glutamine (Invitrogen, 25030), and 100U/mL peni-
cillin/0.1mg/mL streptomycin (Invitrogen, 15140) at 37◦C
in a humidiﬁed atmosphere containing 5% CO2. Aliquots
were taken at 24 h intervals for assessment of cell viability by
trypan blue exclusion.
2.3. Western Blot. Protein lysates were prepared according
to Mahon et al. [6]. Protein concentration was measured
by the BCA Protein Assay (Pierce, Rockford IL, USA) and
the lysates were stored at −80◦C. Equal amounts of protein
were separated by electrophoresis on an SDS-PAGE 12.5
or 15% and transferred to a pvdf membrane as described
[17]. After blocking, the membrane was incubated with pri-
mary antibodies and secondary antibodies. Protein-antibody
complexes were detected by an enhanced chemiluminescence
immunoblotting ECL (Perkin Elmer, Courtaboeuf, France).
2.4. Flow Cytometry. Cells (105 cells) were incubated for
15min in 500 µL of PBS with 2mMCa2+, 2 µL of Annexin V-
FITC, and 0.25 µg of propidium iodide before ﬂow cytometry
analysis on Facscalibur. At least ten thousand events are
acquired for statistical analysis.
2.5. Cell Cycle. Cells (106 cells) were harvested and washed
once with PBS-SVF 5% then permeabilized with PBS 1%
PFA 0.1% saponin for 30min. Cell incubated with PBS-
propidium iodide (PI, 0.5 µg/mL containing RNAse) for
15min before analysis by ﬂow cytometry. Each cell cycle step
was quantiﬁed by counting cellular events in SubG1, G0/G1,
S, and G2.
2.6. Autophagy Inhibition by RNA Silencing. To stably inhibit
autophagy, HIV-1 lentivirus-based vectors were used to in-
troduce shRNAs against ATG7 into cells as previously de-
scribed [18]. Brieﬂy, shRNAs were cloned in FG12 lentivec-
tor, HEK293FT cells were used as packaging cells, and virus
production was performed as previously described [19].
The human ATG7 siRNA sequence was 5′-AGG ATA CAG
CTG GAG TCA G-3′. Negative-control shRNA was used as
already described [20]. To conﬁrm autophagy inhibition by
silencing of ATG7, transduced cells were grown in nutrient
deprived medium (HBSS) in the absence or in the presence
of Baﬁlomycin A and both LC3B I and II form were detected
by Western blot.
2.7. SA-β-Galactosidase Labeling. Cells (106 cells) were wa-
shed with PBS once, before being ﬁxed 4mins with 3% PFA
(paraformaldehyde) then washed once with PBS. Cells were
then incubated in a 96-well plate with a mix (1 vol/20 vol) of
solution I containing X-Gal (20mg/mL X-Gal in dimethyl-
formaldehyde, Promega, V3941) and solution II (5mM
ferricyanure, 5mM ferrocyanure, 2mM MgCl2 150mM
NaCl, 30mM Citric acid/phosphate pH = 6) for 24 hours at
37◦C [21]. Cells were then washed with PBS and SA-β-gal
activity was observed by detection of a bleu staining with an
inverted Nixon Microscope (Eclipse Ti) and analyzed with
the Nikon software NIS. For SA-β-gal-positive staining cell
quantiﬁcation, 100 cells were counted on three separate ﬁelds
and the mean of blue stained cells was calculated as followed
(number of blue cells/(number of total cells)). Results are
expressed as the percent of SA-β-gal-positive cells.
2.8. CD34 Cells Isolation and Culture. Mononuclear cells
were isolated from blood by Ficoll gradient. CD34 pos-
itive cells were puriﬁed according to the manufacturer’s
instructions (Miltenyi Biotech, Germany) and purity was
analyzed by ﬂow cytometry using phycoerythrin-conjugated
anti-CD34 antibody (Becton Dickinson, France). CD34
cells (105/mL) were grown in X-vivo 10 medium supple-
mented with 10% fetal calf serum (FCS; GIBCO, 10270),
2mM L-glutamine (Invitrogen, 25030), and 100U/mL peni-
cillin/0.1mg/mL streptomycin (Invitrogen, 15140) at 37◦C
in a humidiﬁed atmosphere containing 5% CO2. Cells were
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Figure 1: Inhibition of K562 cell proliferation byMPA. K562-S, K562-R and K562-RN cells (2.105/mL) were grown in the presence of vehicle
only, MPA (3 µg/mL) or incubated with guanosine (200 µM) and MPA (3 µg/mL) for 3 days. At day 3, cell proliferation was measured by
counting cells using trypan blue exclusion assay. Cell counts from triplicate counting are expressed as themean of 7 independent experiments
(a). cells treated as described above were ﬁxed, permeabilized then incubated with propidium iodide (PI 2 µg/mL) and analyzed by ﬂow
cytometry for cell cycle measurement. Results are from one experiment representative of ﬁve and are expressed as the percent of cells in
each phase of cell cycle as described in methods (b). MPA-induced phosphorylation of γH2AX was detected by Western blot on samples as
described in (a) (c). Hsp60 was used as loading control.
incubated with vehicle only, imatinib 1 µM, or MPA 3 µg/mL
for 3 days.
2.9. Statistical Analysis. Wilcoxon or Friedman tests were
used to calculate differences between means; differences were
considered signiﬁcant only when P ≤ 0.05.
3. Results
3.1. MPA Inhibits Proliferation of TKI Sensitive or Resistant
K562 Cells by Blocking the Cell Cycle. K562 cells sensitive to
imatinib (K562), resistant to imatinib by overexpression of
Hsp70 (K562-R) or resistant to nilotinib by overexpression
of Lyn kinase (K562-RN) were treated with various doses of
MPA (1 to 10 µg/mL). All showed similar sensitivity to the
drug as assessed by trypan blue exclusion assay. The dose
of 3 µg/mL (9 µM) was chosen for further studies as equally
potent in inducing cell death after two to three days in all
cells (CML cell lines and primary CD34 cells) and in the
range of the plasmatic concentration ofMPA-treated patients
which is in the range of 1 to 4 µg/mL. MPA inhibited cell
proliferation of all three cell lines (Figure 1(a)). Since MPA
inhibits IMPDH thus impairing GTP synthesis, addition of
exogenous guanosine is expected to rescue the effects of
MPA. Addition of guanosine indeed rescued K562 cells from
mortality (supplementary Figure 1), but had a modest effect
on global proliferation even at longer time. Cell cycle analyses
showed that MPA-induced cell death was correlated to a
blockage in the S phase with a weak sub-G1 population in
all three lines (Figure 1(b)). Consistently, phosphorylation of
histone γH2AX, a marker of DNA damage, was induced in
all three cell lines, an effect that was prevented by addition of
guanosine (Figure 1(c)).
3.2. MPA Induces Apoptosis in K562 Cells. In an attempt
to determine how MPA-treated cells died, we ﬁrst look
at apoptosis. Annexin V/Propidium Iodide (PI) labelling
revealed a weak induction of apoptosis in response to MPA
(Figure 2(a)). Even after 3 days of exposure, the number of
annexin V-positive cells remained very low compared to the
4 Leukemia Research and Treatment
∗and∗∗ P ≤ 0.05
0
10
20
30
40
50
60
70
80
N
u
m
b
er
o
f
p
o
si
ti
ve
ce
ll
s
(%
)
ANV+
K562 K562-R K562-RN
MPA +−
− −
+
+
−
−
+
−
+
+
−
−
+
−
+
+Zvad-fmk
K
5
6
2
+
im
at
in
ib
∗∗
∗
∗∗
∗∗
n = 6,
(a)
Cleaved caspase 3
Hsp 60
Cleaved caspase 3
Hsp 60
Cleaved caspase 3
Hsp 60
K562
K562-R
K562-RN
+−
− −
+
+Zvad-fmk
MPA
(b)
Figure 2: MPA induced a moderated apoptosis. K562-S, K562-R, and K562-RN cells (2.105/mL) were grown in the presence of vehicle only,
MPA (3 µg/mL) or incubated with Z-vad-fmk (50 µM) and MPA (3 µg/mL) for 3 days. An aliquot was incubated for 15 min in the presence
of annexin-V and propidium iodide. Samples were analyzed by ﬂow cytometry and labelled cells were analyzed as described in Section 2.
Results from 6 experiments are expressed as the % of annexin V-labelled cells in comparison to a positive control corresponding to imatinib-
treated K562 cells ((a), n = 6). Samples treated as above were used for detection of the cleaved form of caspase 3 by Western blot and Hsp60
(as loading control) (b).
apoptosis induced by imatinib in the TKI-sensitive K562 cell
line (Figure 2(a) last lane). Indeed, the weak apoptosis of
these cells was further conﬁrmed by the measurement of
mitochondrial membrane depolarization using DiOC6 and
of PARP cleavage (data not shown). In addition, inhibition
of caspase by incubation with 50 µMZ-vad-fmk resulted in a
decrease of MPA-induced cleavage of caspase 3 (Figure 2(b))
and in the weak proportion of annexin V-positive cells,
except for the K562-RN cell line (Figure 2(a)). These results
indicate that MPA induces weak apoptosis in the three K562
cell lines. No signiﬁcant necrosis (isolated PI stained cell
population) was detected.
3.3. MPA Induces a Senescent Phenotype in Treated K562 Cells.
To explain themortality of our cells in the absence of necrosis
and with only limited apoptosis, we studied alternative cell
death. Because MPA-treated K562 cells showed an arrest
of cell cycle and an increase of cell granularity by ﬂow
cytometry, we explored markers of senescence such as an
increase of senescence-associated β-Galactosidase activity
(SA-β-gal). The upregulation of p16 and p53, as markers of
senescence, cannot be detected in our cells as these genes
are deleted in K562 cells. A signiﬁcant increase of SA-β-
Gal activity was detected in 70–80% of MPA-treated K562
cells (Figures 3(a) and 3(b)). In addition, MPA induced also
foci formation in the nuclei as revealed by DAPI staining
(supplementary Figure 2). As was observed with global
cell mortality, addition of exogenous guanosine partially
abolished the effects of MPA (Figure 3(b)).
3.4. Autophagy Limits Apoptosis but Not Senescence in
MPA-Treated K562 Cells. Because K562 cells sensitive or
resistant to imatinib or nilotinib respond to MPA by a
senescent-like cell cycle arrest and a weak apoptosis, we
next wondered whether autophagy, a mechanism known to
modulate various cell death mechanisms, could intervene
with MPA-induced K562 cell death. The conversion of the
microtubule-associated protein 1 light chain 3 (LC3) from
its cytosolic form (LC3BI) to the membrane-bound form
(LC3BII) was detected as a bona ﬁde marker of autophagy.
Because autophagy is a ﬂux process, MPA- increased LC3BII
is visualized by the addition of Baﬁlomycin A1 (20 nM) 6
hours before the end of MPA incubation. Both forms of LC3
(Figure 4(a)) are upregulated in K562 cells following MPA
treatment, indicating that autophagy is actually stimulated
in this condition. This was conﬁrmed by SQSTM1/p62
detection by Western blotting (supplementary Figure 3(a)).
In order to understand whether autophagy modulates
MPA-induced cell death, we incubated the cells with 3-
methyladenine (3-MA) or chloroquine (CQ), two drugs
known to inhibit autophagy. MPA-induced apoptosis of
K562 cells was signiﬁcantly increased (2 to 3 fold) when cells
were coincubated with 3-MA and MPA or to even higher
levels after CQ treatment (supplementary Figures 3(b) and
3(d) available online at Doi:10.1155/2012/861301), indicat-
ing that autophagy physiologically limits MPA-induced cell
apoptosis.
We next asked whether autophagy could also alter the
MPA-induced senescent-like cell cycle arrest. After treatment
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Figure 3: MPA induced SA-β-Galactosidase activity. K562-S, K562-R, and K562-RN cells (2.105/mL) were grown in the presence of vehicle
only or MPA (3 µg/mL) for 3 days. An aliquot was washed in PBS and 105 cells/well were ﬁxed in PFA and then incubated overnight in a
96-well plate in the presence of X-Gal (1mg/mL) at 37◦C as described in Section 2. The day after, the cells were washed once in PBS and
SA-β-gal activity was detected by a blue cell staining visualized under an inverted microscope. Pictures were acquired and analyzed using
the NIS Nikon software (a). SA-β-gal-positive cells were quantiﬁed by counting 102 cells on three separate ﬁelds for each condition. Results
show the mean of ﬁve independent experiments (b).
of the cells with 3-MA, MPA-induced SA-β-gal activity
was not signiﬁcantly modiﬁed (supplementary Figure 3(c)),
suggesting that inhibition of autophagy had no effect in
modulating the senescent response. Chloroquine inhibits
the revelation of SA-β-gal activity by modifying the pH
of lysosomes and we could not use it to emphasize a
potential role of autophagy in senescence. As an alternative,
we inhibited autophagy by RNA silencing (shRNAs) to
shut down the expression of ATG7, a major player of
autophagy whose downregulation has been shown to be
inhibitory. Inhibition of ATG7 expression was conﬁrmed
by Western blotting (Figure 4(b)) and strongly decreased
MPA- induced autophagy as reported the decrease of LC3BII
level (Figure 4(a)). Even though the expression of ATG7
was completely abolished, no signiﬁcant difference in MPA-
induced SA-β-gal activity was observed suggesting that
autophagy does not alter MPA induced senescent-like cell
cycle arrest (Figure 4(b)).
3.5. MPA Overcomes Resistance in Primary CD34 CML Cells.
The efficacy of MPA was investigated on CD34 primary cells
isolated from blood samples of CML patients responding to
imatinib (patient 1) or resistant to imatinib and nilotinib
(patient 2 to 4). Patient 2 and 3 overexpressed several tyrosine
kinase such as Src-kinase whereas patient 4 was mutated on
Abl kinase domain carrying the mutation T315I. All primary
cells were grown in the presence of vehicle only, imatinib
1 µM, or MPA 3 µg/mL for 3 days. Annexin-V binding and
SA-β-Gal was detected at days 0 and upon treatment at day 3.
Apoptosis was signiﬁcantly detected for patient 1 in response
to imatinib or MPA. For imatinib- or nilotinib- resistant
CML patients only MPA induced apoptosis (Figure 5). When
SA-β-Gal was revealed, no signiﬁcant labeling was detected
despite an increase in cell size and morphology observed
in ﬂow cytometry suggesting that primary cells respond
mainly by apoptosis (supplementary Figure 4). Because
MPA induced apoptosis of CD34 CML cells, we looked
at a possible synergy with imatinib. Interestingly, CD34
cells of TKI sensitive CML patient respond to imatinib by
apoptosis but addition of MPA did not increase the apoptotic
response (supplementary Figure 5(a)). In contrast, CD34
cells from TKI- resistant patient did not respond to imatinib
as suspected but achieved apoptosis in response to MPA. The
response of CD34 CML cells to MPA is partially reverted
by guanosine addition (supplementary Figure 5(b)) even for
the highest MPA concentration required to reach the optimal
apoptotic response (supplementary Figure 5(c)).
4. Discussion
Despite the major improvement of CML patients’ manage-
ment due to anti-Abl TKIs, one issue remains to be resolved:
the emergence of resistances to TKI and relapse [22, 23].
Whatever the mechanisms implicated, they are linked to
an impaired TKI-induced apoptosis [24, 25]. This explains
that drugs triggering alternative cell death mechanisms are
very interesting potential therapeutic tools. MPA is efficiently
killing K562 cells, including those resistant to imatinib and
nilotinib harbouring differentmechanism of resistance.MPA
increase mortality of our cells, a speciﬁc response since the
addition of guanosine prevents it. However, the lack of a
total restoration of cell proliferation by guanosine indicates
that MPA may also act by other ways although guanosine
used at 200 µM may be not enough to reﬁll the GTP
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Figure 4: MPA induced autophagy in K562 cells. K562-S, K562-R, and K562-RN cells (2.105/mL) were grown in the presence of vehicle
only or MPA (3 µg/mL) for 3 days. Six hours before the end of the incubation, samples were separated in two batches and incubated in the
absence or in the presence of baﬁlomycin A1 (20 nM) to block the autophagic ﬂux. Then, K562 cells were washed once in PBS and lyzed
in a modiﬁed RIPA buffer for detection by Western blot of LC3B and Hsp60 (as a loading control) (a). K562-S, K562-R and K562-RN cells
(2.105/mL) were infected by lentivirus coding for a shRNA anti-ATG7. Lentiviral particles were incubated for 24 h with K562 cells. Then, the
cells were washed twice in PBS and grown in the presence of medium for 6 days before sorting based on GFP expression and experimental
use. After 3 days, each sample was analysed for ATG7 inhibition by Western blotting (b). K562-S, K562-R, and K562-RN cells (2.105/mL)
and K562-S, K562-R, and K562-RN cells (2.105/mL) deﬁcient for ATG7 were grown in the presence of vehicle only, MPA (3 µg/mL). After 3
days, SA-β-gal-positive cells were quantiﬁed by counting 102 cells on three separate ﬁelds for each condition (c). Results show the mean of
three experiments.
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Figure 5: MPA induced apoptosis in CD34 CML cells. Primary CD34 cells isolated from blood samples of CML patients responding to
imatinib (patient 1) or resistant to imatinib and nilotinib (patient 2 to 4) were grown in the presence of vehicle only, imatinib 1 µM, or MPA
3 µg/mL for 3 days. Patient 2 and 3 overexpressed several tyrosine kinase such as Src-kinase, whereas patient 4 was mutated in Abl kinase
domain harbouring the T315I mutation. Annexin-V binding was detected at day 0 and upon treatment at day 3.
pool. Using CD34 CML cells, a similar abrogation effect
of MPA was observed with guanosine. A synergy between
MPA and imatinib has been reported using CML cell lines
which partially overcome resistance to TKI [13]. We did not
detect such synergy between imatinib and MPA in CD34
CML cells. It may be because in primary cells, MPA at the
concentration used is not able to potentiate imatinib effect.
In our hands, MPA alone blocks the cell cycle and induces
the death of K562 cells, either sensitive or rendered resistant
to TKI. Inhibition of cell cycle by MPA is associated to a
blockade to proceed in the S phase. This is similar to the
arrest reported by Moosavi et al. using GTP depletion [26].
Apoptosis accounts for only a limited part of MPA-induced
K562 death and can be inhibited by preincubation with Z-
vad-fmk, a broad inhibitor of caspase. Caspase3 cleavage
occurred in all three lines, including K562-RN although the
effect of Z-vad-fmk was extremely weak in this particular cell
line. This would suggest that the modiﬁcations of tyrosine
kinome generated when rendering these cells resistant to TKI
may be involved for a switch towards a caspase-independant
apoptosis. This hypothesis is in line with the fact that
tyrosine-kinase activity (several are overexpressed in K562-
RN) inﬂuences DNA damage and caspase-independent
apoptosis as shown in breast cancer cells [6, 27]. This could
also explain that H2AX phosphorylation in response to
MPA is lower in K562-RN cells compared to the other two
lines which do not overexpress tyrosine-kinases. A caspase-
independent cell death has been reported in Bcr-Abl-positive
cells treated by a combination of TKI and Z-Vad-fmk which
harbour a necrosis-like phenotype [28]. In their model,
Okada et al. show the role of the serine protease Omi/HtrA2
in a necrosis-like death. This death could be involved in the
response of K562 cells to MPA. However, incubation with the
serine protease inhibitor ucf-101, which inhibits Omi/HtrA2,
did not modify MPA-induced cell death suggesting again a
different death than necrosis (data not shown).
In addition to the weak apoptotic response, we have ob-
served a large and signiﬁcant senescent-like cell cycle arrest in
MPA-treated K562 cells associated to a large increase in SA-
β-galactosidase-positive cells. This would suggest that MPA
induced senescence in K562 cells. Indeed, stress induced
senescence can be triggered by p53-dependent pathways and
p16/INK4 upregulation. However, these pathways cannot
be activated in our cells in which these genes are deleted.
Senescence has been shown to be triggered by p53- and
p16- independent pathway that could be indirectly through
cell cycle arrest and ATM activation [29, 30]. Indeed, the
senescent response is not the behavior of K562 cells alone
8 Leukemia Research and Treatment
but also occurred in lama-84 and AR-230 cells and it was in
a similar proportion than apoptosis. In contrast, some other
cell lines respond to MPA by apoptosis only like KCL22 or
Baf3 cells expressing Bcr-Abl (Drullion, unpublished results).
MPA is able to block proliferation and to induce death
of primary CD34 CML cells either sensitive or resistant to
imatinib or nilotinib. Although CD34 CML cells respond to
MPA mainly by apoptosis, it may be a powerful tool in the
evolved CML disease or TKI resistant like those harbouring
the T315I mutation or overexpressing tyrosine kinases. This
also suggests that K562 cells possess additional molecular
anomalies that rely on the blast phase. Despite an arrest
of proliferation, we were not able to detect SA-β-Gal in
MPA-treated CD34 CML cells. Interestingly, RNA silencing
of p53 in other CML cell line did not switch MPA- induced
apoptosis to a senescent response conﬁrming that other
candidates play roles (Drullion, unpublished results).
Since autophagy has been shown to induce cell surviving
by the rescue of the cells from apoptosis or by cell death
depending on the cellular context, we thought of interest to
study this response in MPA-treated K562 cells. The increased
expression of LC3B indicates that MPA induced autophagy
certainly through the inhibition of the mTor pathway as
suggested by the study of Gu et al. [13]. To the best of
our knowledge, this is the ﬁrst report showing that MPA
is able to induce autophagy in CML cells. Autophagy has
been shown to rescue CML cells from TKI-induced apoptosis
[31–33]. Here, we see that the similar thing happens in
MPA-treated cells and that inhibition of autophagy increases
apoptosis in the K562- treated cells. This emphasizes that
MPA- induced apoptosis is weak partially because the cells
are rescued by autophagy. Regarding senescence, however,
we failed to observe any effect of autophagy inhibition.
The inhibition of autophagy by anti-ATG7 shRNA did not
abolish or modify MPA-induced senescent-like cell cycle
arrest. In light of what was described about the positive
role of autophagy on stress-induced senescence, different
mechanisms may explain the absence of regulation of MPA-
induced senescence by autophagy in our model [34]. Even
no signiﬁcant inhibitory role of autophagy has been pointed
out, the senescent response did not require an upstream
autophagic response to occur as the inhibition of the later
did not abolish senescence. It will be interesting to check in
our model if the lack of a positive regulation of senescence
by autophagy is correlated to the absence of expression of
the different autophagic-related genes discovered to be up-
regulated during senescence [34]. Another explanation may
be that MPA- induced autophagy by noncanonical pathway
like it was described for resveratrol [35, 36]. This peculiar
pathway triggering a noncanoical autophagy is described
independent of Beclin 1 and of inhibition of Vps34, a PI3
kinase, by 3 MA. In our hands, 3-MA was inhibiting MPA-
induced autophagy leading to an increase of cell mortality
mainly by apoptosis but not by senescence. The inhibition
of the expression of ATG7 in K562 cells decreases autophagy
although it failed to fully block the transformation of LC3BI
in LC3BII suggesting that residual autophagy can occur. This
could explain why we were unable to demonstrate a link
between autophagy and senescence in response to MPA.
Moreover, the inhibition of autophagy by 3 MA or siRNA
against LC3 did not change the senescence response to MPA
arguing for an absence of role. These results also highlight
that the relations between the different deaths observed in
a speciﬁc model are not a constant rule. We were not able
to demonstrate an inhibition or conversely potentiating of
MPA-induced senescent-like cell cycle arrest whatever the
way used to block autophagy. Indeed, this suggests that in
contrast to apoptosis, autophagy is not able to rescue MPA-
treated cells from senescence.
One interesting point to induce a senescent-like cell cycle
arrest or apoptosis in CML disease is that resistance to TKI-
treatment and persistence of leukemic cells are associated to
relapse and the evolution of the disease. MPA is able to target
both, CML cells of the chronic phase, like we did with CML
primary cells, and blastic cells, like we did with CML cell
lines. Such molecule is actively looked for. In conclusion,
molecules triggering cell death independently of tyrosine
kinase inhibition are interesting tools to get rid of resistant
CML cells and may be one way to check in blast cells from
acute leukemia.MPAwhich triggers apoptosis and senescent-
like cell cycle arrest is one of these interesting drugs.
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